Denbufylline

Denbufylline (BRL 30892) is an inhibitor of phosphodiesterase-4 (PDE4) . Denbufylline is able to block the degradation of intracellular cAMP (cyclic adenosine phosphate) thereby increasing the level of intracellular cAMP, which helps regulate a variety of cellular functions. Denbufylline can be used in the study of chronic obstructive pulmonary disease (COPD), asthma and other inflammatory diseases[1].

Product Specifications

CAS Number

[57076-71-8]

Product Name Alternative

BRL 30892

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Others

Assay Protocol

https://www.medchemexpress.com/denbufylline.html

Purity

99.92

Solubility

DMSO : 33 mg/mL (ultrasonic; warming)

Smiles

O=C(N1CCCC)N(CCCC)C2=C(N(CC(C)=O)C=N2)C1=O

Molecular Formula

C16H24N4O3

Molecular Weight

320.39

References & Citations

[1]Martin L, et al. Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels[J]. European journal of pharmaceutics and biopharmaceutics, 2003, 55 (1) : 35-45.